This article is more than 5 years old. Information may no longer be current.

TLC Vision launches subsidiary dedicated to treating dry AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

MISSISSAUGA, Ontario — A chain of clinics devoted to the treatment of dry age-related macular degeneration was launched here Nov. 25.

TLC Vision Corp. launched Rheo Clinic Inc., a subsidiary dedicated to the treatment of dry AMD using the blood filtration process called rheopheresis.

Rheopheresis, performed using the Rheofilter MDF System (OccuLogix LP), is designed to deplete certain high molecular weight plasma proteins and lipoproteins from the blood. These proteins are believed to contribute to the development or promote the progression of dry AMD.

According to a company press release, the TLC subsidiary will develop, own and manage its commercial facilities. The first Rheo Clinic facility is located within TLC Vision’s international headquarters here.

Patient consultations at the facility were set to begin this week, and the first treatment was expected November 26.